[go: up one dir, main page]

DE69631774D1 - 2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate - Google Patents

2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate

Info

Publication number
DE69631774D1
DE69631774D1 DE69631774T DE69631774T DE69631774D1 DE 69631774 D1 DE69631774 D1 DE 69631774D1 DE 69631774 T DE69631774 T DE 69631774T DE 69631774 T DE69631774 T DE 69631774T DE 69631774 D1 DE69631774 D1 DE 69631774D1
Authority
DE
Germany
Prior art keywords
dioxo
tetrahydro
chinoxaline
derivatives
chinoxaline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631774T
Other languages
English (en)
Other versions
DE69631774T2 (de
Inventor
Pierre Acklin
Hans Allgeier
Yves Auberson
Michel Biollaz
Robert Moretti
Silvio Ofner
Jacob Veenstra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69631774D1 publication Critical patent/DE69631774D1/de
Application granted granted Critical
Publication of DE69631774T2 publication Critical patent/DE69631774T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69631774T 1995-08-31 1996-08-19 2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate Expired - Lifetime DE69631774T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CH247995 1995-08-31
CH247995 1995-08-31
CH273495 1995-09-27
CH273495 1995-09-27
CH274795 1995-09-28
CH274795 1995-09-28
CH121396 1996-05-10
CH121396 1996-05-10
CH163096 1996-06-28
CH163096 1996-06-28
PCT/EP1996/003644 WO1997008155A1 (en) 1995-08-31 1996-08-19 Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives

Publications (2)

Publication Number Publication Date
DE69631774D1 true DE69631774D1 (de) 2004-04-08
DE69631774T2 DE69631774T2 (de) 2005-01-13

Family

ID=27508939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631774T Expired - Lifetime DE69631774T2 (de) 1995-08-31 1996-08-19 2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate

Country Status (25)

Country Link
US (1) US6080743A (de)
EP (1) EP0853617B1 (de)
JP (1) JP3159711B2 (de)
KR (1) KR100462337B1 (de)
CN (1) CN1137886C (de)
AR (1) AR005229A1 (de)
AT (1) ATE260902T1 (de)
AU (1) AU705871B2 (de)
BR (1) BRPI9603626B8 (de)
CA (1) CA2227851C (de)
CZ (1) CZ56298A3 (de)
DE (1) DE69631774T2 (de)
DK (1) DK0853617T3 (de)
ES (1) ES2217324T3 (de)
HU (1) HUP9801676A3 (de)
IL (1) IL122987A (de)
MY (1) MY132385A (de)
NO (1) NO310236B1 (de)
NZ (1) NZ316497A (de)
PL (1) PL189637B1 (de)
PT (1) PT853617E (de)
SI (1) SI0853617T1 (de)
SK (1) SK25298A3 (de)
TR (1) TR199800349T2 (de)
WO (1) WO1997008155A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3133697A (en) * 1996-06-05 1998-01-05 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
ES2264171T3 (es) * 1996-10-24 2006-12-16 Novartis Ag Acidos aminoalcanofosfonicos sustituidos.
ZA9710553B (en) * 1996-11-25 1998-06-10 Warner Lambert Co Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists.
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
US6096744A (en) * 1998-05-04 2000-08-01 Warner-Lambert Company Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US7361666B2 (en) 1999-05-25 2008-04-22 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
AU2001216218A1 (en) * 2000-05-25 2001-12-11 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
EP1436258A4 (de) * 2001-03-08 2005-03-23 Univ Emory Ph-wert-abhängige nmda-rezeptorantagonisten
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
MXPA06003578A (es) * 2003-09-30 2006-08-31 Johnson & Johnson Compuestos de quinoxalina.
US20060020029A1 (en) * 2004-07-02 2006-01-26 Shimasaki Craig D Pharmaceutical compositions from ethnobotanicals
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
JP2010532382A (ja) * 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのnmda受容体拮抗薬
CN102906085A (zh) * 2010-05-20 2013-01-30 诺瓦提斯公司 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
EP3573960B1 (de) * 2017-01-27 2023-08-16 Genfit N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2h-1,4-benzoxazin-7-yl)acetamid-derivate und verwandte verbindungen als ror-gamma modulatoren zur behandlung von autoimmunerkrankungen
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
WO1991001724A1 (en) * 1989-07-27 1991-02-21 G.D. Searle & Co. Renal-selective prodrugs for the treatment of hypertension
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) * 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
KR100462337B1 (ko) 2005-02-28
SI0853617T1 (en) 2004-08-31
PT853617E (pt) 2004-06-30
WO1997008155A1 (en) 1997-03-06
JPH11511444A (ja) 1999-10-05
EP0853617A1 (de) 1998-07-22
CZ56298A3 (cs) 1998-06-17
NO980814D0 (no) 1998-02-26
HUP9801676A2 (hu) 1999-03-29
MY132385A (en) 2007-10-31
ES2217324T3 (es) 2004-11-01
AU705871B2 (en) 1999-06-03
DK0853617T3 (da) 2004-07-05
NO310236B1 (no) 2001-06-11
EP0853617B1 (de) 2004-03-03
AR005229A1 (es) 1999-04-28
IL122987A (en) 2001-08-08
PL189637B1 (pl) 2005-09-30
MX9801643A (es) 1998-08-30
AU6874296A (en) 1997-03-19
TR199800349T2 (xx) 1998-09-21
BRPI9603626B8 (pt) 2021-07-06
KR19990044275A (ko) 1999-06-25
NO980814L (no) 1998-04-21
HUP9801676A3 (en) 1999-04-28
SK25298A3 (en) 1998-09-09
NZ316497A (en) 2000-01-28
PL324992A1 (en) 1998-07-06
ATE260902T1 (de) 2004-03-15
CA2227851C (en) 2009-01-06
HK1010196A1 (en) 1999-06-17
IL122987A0 (en) 1998-08-16
BRPI9603626B1 (pt) 2016-08-23
US6080743A (en) 2000-06-27
CA2227851A1 (en) 1997-03-06
JP3159711B2 (ja) 2001-04-23
DE69631774T2 (de) 2005-01-13
CN1193968A (zh) 1998-09-23
CN1137886C (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
DE69631774D1 (de) 2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate
DE69613368D1 (de) Chinazolin derivate
DE69613369D1 (de) Chinazolin derivate
DE69613367D1 (de) Chinazolin derivate
ATE264327T1 (de) Substituierte 6,6-heterobicyclische derivate
ATE228510T1 (de) Substituierte 1,2,3,4-tetrahydronaphthalin derivate
ATE446955T1 (de) Chinazolinone derivate
DE122004000018I1 (de) 4"-Substitutierte-9-Deoxo-9A-Aza-9A-Homoerythromycin a Derivate.
DE69706292D1 (de) Chinazoline derivate
DE69736711D1 (de) Substituierte 6,5-heterobicyclische-derivate
MA23780A1 (fr) Quinazolinones 2, 8 disubstitues
ATE314387T1 (de) Dolastatin 15 derivate
DE69618634D1 (de) 1,4-benzodioxin-derivate
FI952424L (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
ATE277917T1 (de) Alkylaminobenzothiazole und -benzoxazole derivate
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE69600292D1 (de) Cyclodextrin Derivate
DE69611758D1 (de) N-1-carbocylalkyl derivate von lsd
ATE241599T1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalcerifer l derivate
DE69622415D1 (de) 12H-Dibenzo[d,g][1,3]dioxocin Derivate
ATE240941T1 (de) 1,25-dihydroxy-16,22,23-trisdehydro- cholecalciferol-derivate
DE69635901D1 (de) Polycyclische derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN